292 related articles for article (PubMed ID: 9029030)
1. Long-term follow-up of leukaemia patients after related cryopreserved allogeneic bone marrow transplantation.
Stockschläder M; Hassan HT; Krog C; Krüger W; Löliger C; Horstman M; Altnöder M; Clausen J; Grimm J; Kabisch H; Zander A
Br J Haematol; 1997 Feb; 96(2):382-6. PubMed ID: 9029030
[TBL] [Abstract][Full Text] [Related]
2. Transplantation of peripheral blood progenitor cells from HLA-identical sibling donors. European Group for Blood and Marrow Transplantation (EBMT).
Schmitz N; Bacigalupo A; Labopin M; Majolino I; Laporte JP; Brinch L; Cook G; Deliliers GL; Lange A; Rozman C; Garcia-Conde J; Finke J; Domingo-Albos A; Gratwohl A
Br J Haematol; 1996 Dec; 95(4):715-23. PubMed ID: 8982051
[TBL] [Abstract][Full Text] [Related]
3. Factors influencing the haematological recovery after allogeneic bone marrow transplantation in leukaemia patients treated with methotrexate-containing GVHD prophylaxis: a single-centre experience.
Hassan HT; Krog C; Stockschläder M; Schleimer B; Zeller W; Krüger W; Erttmann R; Zander AR
Anticancer Res; 1997; 17(1B):589-99. PubMed ID: 9066585
[TBL] [Abstract][Full Text] [Related]
4. Use of cryopreserved bone marrow in allogeneic bone marrow transplantation.
Stockschläder M; Krüger W; Kroschke G; Zeller W; Hoffknecht M; Löliger C; Kabisch H; Zander A
Bone Marrow Transplant; 1995 Apr; 15(4):569-72. PubMed ID: 7655383
[TBL] [Abstract][Full Text] [Related]
5. Comparison of outcome of allogeneic bone marrow transplantation with and without granulocyte colony-stimulating factor (lenograstim) donor-marrow priming in patients with chronic myelogenous leukemia.
Ji SQ; Chen HR; Wang HX; Yan HM; Pan SP; Xun CQ
Biol Blood Marrow Transplant; 2002; 8(5):261-7. PubMed ID: 12064363
[TBL] [Abstract][Full Text] [Related]
6. Allogeneic bone marrow transplantation from unrelated donors using in vivo anti-T-cell globulin.
Finke J; Bertz H; Schmoor C; Veelken H; Behringer D; Wäsch R; Kunzmann R; Heidecker L; Lang H; Meyer-König U; Mertelsmann R
Br J Haematol; 2000 Oct; 111(1):303-13. PubMed ID: 11091217
[TBL] [Abstract][Full Text] [Related]
7. Allogeneic bone marrow transplantation for chronic myeloid leukemia using HLA identical sibling donors primed with G-CSF.
Chen HR; Ji SQ; Wang HX; Yan HM
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2002 Aug; 10(4):340-6. PubMed ID: 12513770
[TBL] [Abstract][Full Text] [Related]
8. Allogeneic cell-mediated immunotherapy using donor lymphocytes for prevention of relapse in patients treated with allogeneic bone marrow transplantation for hematological malignancies.
Naparstek E; Nagler A; Or R; Kapelushnik J; Slavin S
Clin Transpl; 1996; ():281-90. PubMed ID: 9286578
[TBL] [Abstract][Full Text] [Related]
9. Allogeneic hematopoietic cell transplantation without myeloablative conditioning for patients with advanced hematologic malignancies.
Gürman G; Arat M; Ilhan O; Konuk N; Beksaç M; Celebi H; Ozcan M; Arslan O; Ustün C; Akan H; Uysal A; Koç H
Cytotherapy; 2001; 3(4):253-60. PubMed ID: 12171713
[TBL] [Abstract][Full Text] [Related]
10. Use of cryopreserved bone marrow in unrelated allogeneic transplantation.
Stockschläder M; Krüger W; tom Dieck A; Horstmann M; Altnöder M; Löliger C; Fiedler W; Hoffknecht M; Erttmann R; Zander A
Bone Marrow Transplant; 1996 Feb; 17(2):197-9. PubMed ID: 8640166
[TBL] [Abstract][Full Text] [Related]
11. Hematopoietic and immune recovery after allogeneic peripheral blood stem cell transplantation and bone marrow transplantation in a pediatric population.
Nagatoshi Y; Kawano Y; Watanabe T; Abe T; Okamoto Y; Kuroda Y; Takaue Y; Okamura J
Pediatr Transplant; 2002 Aug; 6(4):319-26. PubMed ID: 12234273
[TBL] [Abstract][Full Text] [Related]
12. Distinct patterns of minimal residual disease associated with graft-versus-host disease after allogeneic bone marrow transplantation for chronic myelogenous leukemia.
Pichert G; Roy DC; Gonin R; Alyea EP; Bélanger R; Gyger M; Perreault C; Bonny Y; Lerra I; Murray C
J Clin Oncol; 1995 Jul; 13(7):1704-13. PubMed ID: 7602361
[TBL] [Abstract][Full Text] [Related]
13. Treatment with granulocyte colony-stimulating factor after allogeneic bone marrow transplantation for acute leukemia increases the risk of graft-versus-host disease and death: a study from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation.
Ringdén O; Labopin M; Gorin NC; Le Blanc K; Rocha V; Gluckman E; Reiffers J; Arcese W; Vossen JM; Jouet JP; Cordonnier C; Frassoni F
J Clin Oncol; 2004 Feb; 22(3):416-23. PubMed ID: 14691124
[TBL] [Abstract][Full Text] [Related]
14. Risk factors in bone marrow transplant recipients with leukaemia. Increased relapse risk in patients treated with ciprofloxacin for gut decontamination.
Carlens S; Ringdén O; Aschan J; Hägglund H; Ljungman P; Mattsson J; Remberger M
Clin Transplant; 1998 Apr; 12(2):84-92. PubMed ID: 9575394
[TBL] [Abstract][Full Text] [Related]
15. Comparison of engraftment and acute GVHD in patients undergoing cryopreserved or fresh allogeneic BMT.
Eckardt JR; Roodman GD; Boldt DH; Clark GM; Alvarez R; Page C; Gaskill H; LeMaistre CF
Bone Marrow Transplant; 1993 Feb; 11(2):125-31. PubMed ID: 8435661
[TBL] [Abstract][Full Text] [Related]
16. Allogeneic blood stem cell transplantation for refractory leukemia and lymphoma: potential advantage of blood over marrow allografts.
Körbling M; Przepiorka D; Huh YO; Engel H; van Besien K; Giralt S; Andersson B; Kleine HD; Seong D; Deisseroth AB
Blood; 1995 Mar; 85(6):1659-65. PubMed ID: 7888684
[TBL] [Abstract][Full Text] [Related]
17. Peripheral blood stem cell graft compared to bone marrow after reduced intensity conditioning regimens for acute leukemia: a report from the ALWP of the EBMT.
Savani BN; Labopin M; Blaise D; Niederwieser D; Ciceri F; Ganser A; Arnold R; Afanasyev B; Vigouroux S; Milpied N; Hallek M; Cornelissen JJ; Schwerdtfeger R; Polge E; Baron F; Esteve J; Gorin NC; Schmid C; Giebel S; Mohty M; Nagler A
Haematologica; 2016 Feb; 101(2):256-62. PubMed ID: 26565001
[TBL] [Abstract][Full Text] [Related]
18. Possible clinical benefits of the use of peripheral blood stem cells over bone marrow in the allogeneic transplantation setting for the treatment of childhood leukemia.
Matsubara H; Makimoto A; Takayama J; Higa T; Saito T; Kanda Y; Tanosaki R; Mineishi S; Ohira M; Takaue Y
Jpn J Clin Oncol; 2001 Jan; 31(1):30-4. PubMed ID: 11256838
[TBL] [Abstract][Full Text] [Related]
19. A potential graft-versus-leukemia effect after allogeneic hematopoietic stem cell transplantation for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: results from the French Bone Marrow Transplantation Society.
Espérou H; Boiron JM; Cayuela JM; Blanchet O; Kuentz M; Jouet JP; Milpied N; Cahn JY; Faucher C; Bourhis JH; Michallet M; Tanguy ML; Vernant JP; Gabert J; Bordigoni P; Ifrah N; Baruchel A; Dombret H;
Bone Marrow Transplant; 2003 May; 31(10):909-18. PubMed ID: 12748668
[TBL] [Abstract][Full Text] [Related]
20. A retrospective comparison of allogeneic peripheral blood stem cell and bone marrow transplantation results from a single center: a focus on the incidence of graft-vs.-host disease and relapse.
Ustün C; Arslan O; Beksaç M; Koç H; Gürman G; Ozçelik T; Yilmaz B; Ilhan O; Akan H; Ozcan M; Demirer T; Uysal A; Konuk N; Arat M; Dilek I; Celebi H; Coskun HS
Biol Blood Marrow Transplant; 1999; 5(1):28-35. PubMed ID: 10232738
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
